176 related articles for article (PubMed ID: 24369313)
1. T2 enhances in situ level of Foxp3+ regulatory cells and modulates inflammatory cytokines in Crohn's disease.
Li G; Ren J; Wang G; Gu G; Hu D; Ren H; Hong Z; Wu X; Liu S; Li J
Int Immunopharmacol; 2014 Feb; 18(2):244-8. PubMed ID: 24369313
[TBL] [Abstract][Full Text] [Related]
2. Triptolide downregulates Treg cells and the level of IL-10, TGF-β, and VEGF in melanoma-bearing mice.
Liu B; Zhang H; Li J; Lu C; Chen G; Zhang G; Lu A; He X
Planta Med; 2013 Oct; 79(15):1401-7. PubMed ID: 23975869
[TBL] [Abstract][Full Text] [Related]
3. Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17.
Li Y; Yu C; Zhu WM; Xie Y; Qi X; Li N; Li JS
Mol Immunol; 2010 Sep; 47(15):2467-74. PubMed ID: 20615550
[TBL] [Abstract][Full Text] [Related]
4. Triptolide ameliorates Crohn's colitis is associated with inhibition of TLRs/NF-κB signaling pathway.
Yu C; Shan T; Feng A; Li Y; Zhu W; Xie Y; Li N; Li J
Fitoterapia; 2011 Jun; 82(4):709-15. PubMed ID: 21376787
[TBL] [Abstract][Full Text] [Related]
5. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohn's disease patients.
Reikvam DH; Perminow G; Lyckander LG; Gran JM; Brandtzaeg P; Vatn M; Carlsen HS
Scand J Gastroenterol; 2011 May; 46(5):550-60. PubMed ID: 21281255
[TBL] [Abstract][Full Text] [Related]
6. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease.
Kelsen J; Agnholt J; Hoffmann HJ; Rømer JL; Hvas CL; Dahlerup JF
Clin Exp Immunol; 2005 Sep; 141(3):549-57. PubMed ID: 16045746
[TBL] [Abstract][Full Text] [Related]
7. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of triptolide on interleukin-10 gene-deficient mice with colitis.
Wei X; Gong J; Zhu J; Niu L; Zhu W; Li N; Li J
Int Immunopharmacol; 2008 Dec; 8(13-14):1808-12. PubMed ID: 18804190
[TBL] [Abstract][Full Text] [Related]
9. Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells.
Cook L; Stahl M; Han X; Nazli A; MacDonald KN; Wong MQ; Tsai K; Dizzell S; Jacobson K; Bressler B; Kaushic C; Vallance BA; Steiner TS; Levings MK
Gastroenterology; 2019 Dec; 157(6):1584-1598. PubMed ID: 31513797
[TBL] [Abstract][Full Text] [Related]
10. The suppressive effect of triptolide on chronic colitis and TNF-alpha/TNFR2 signal pathway in interleukin-10 deficient mice.
Wei X; Gong J; Zhu J; Wang P; Li N; Zhu W; Li J
Clin Immunol; 2008 Nov; 129(2):211-8. PubMed ID: 18757245
[TBL] [Abstract][Full Text] [Related]
11. IL-15 interferes with suppressive activity of intestinal regulatory T cells expanded in Celiac disease.
Zanzi D; Stefanile R; Santagata S; Iaffaldano L; Iaquinto G; Giardullo N; Lania G; Vigliano I; Vera AR; Ferrara K; Auricchio S; Troncone R; Mazzarella G
Am J Gastroenterol; 2011 Jul; 106(7):1308-17. PubMed ID: 21468011
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease.
Wang Y; Liu XP; Zhao ZB; Chen JH; Yu CG
J Dig Dis; 2011 Aug; 12(4):286-94. PubMed ID: 21791023
[TBL] [Abstract][Full Text] [Related]
13. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease.
Saruta M; Yu QT; Fleshner PR; Mantel PY; Schmidt-Weber CB; Banham AH; Papadakis KA
Clin Immunol; 2007 Dec; 125(3):281-90. PubMed ID: 17897887
[TBL] [Abstract][Full Text] [Related]
14. Triptolide promotes generation of FoxP3+ T regulatory cells in rats.
Zhang G; Liu Y; Guo H; Sun Z; Zhou YH
J Ethnopharmacol; 2009 Aug; 125(1):41-6. PubMed ID: 19560530
[TBL] [Abstract][Full Text] [Related]
15. Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
Wang Y; Mei Y; Feng D; Xu L
J Neurosci Res; 2008 Aug; 86(11):2441-9. PubMed ID: 18438925
[TBL] [Abstract][Full Text] [Related]
16. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease.
Rismo R; Olsen T; Cui G; Paulssen EJ; Christiansen I; Johnsen K; Florholmen J; Goll R
Scand J Gastroenterol; 2013 Mar; 48(3):311-9. PubMed ID: 23302000
[TBL] [Abstract][Full Text] [Related]
17. Triptolide ameliorates ileocolonic anastomosis inflammation in IL-10 deficient mice by mechanism involving suppression of miR-155/SHIP-1 signaling pathway.
Wu R; Li Y; Guo Z; Gong J; Zhu W; Li N; Li J
Mol Immunol; 2013 Dec; 56(4):340-6. PubMed ID: 23911388
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL) -17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis.
Dutzan N; Gamonal J; Silva A; Sanz M; Vernal R
J Clin Periodontol; 2009 May; 36(5):396-403. PubMed ID: 19419438
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
[TBL] [Abstract][Full Text] [Related]
20. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
